149 related articles for article (PubMed ID: 17622496)
1. Tumour markers in internal medicine: a low-cost test or an unnecessary expense? A retrospective study based on appropriateness.
Arioli D; Pipino M; Boldrini E; Amateis E; Cristani A; Ventura P; Romagnoli E; De Santis MC; Zeneroli ML
Intern Emerg Med; 2007 Jun; 2(2):88-94. PubMed ID: 17622496
[TBL] [Abstract][Full Text] [Related]
2. An audit of tumour marker utilization in Greece.
Ntaios G; Hatzitolios A; Chatzinikolaou A; Karalazou P; Savopoulos C; Karamouzis M; Pidonia I
Eur J Intern Med; 2009 May; 20(3):e66-9. PubMed ID: 19393482
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in the treatment of cancer: opportunities and pitfalls.
Melichar B
Clin Chem Lab Med; 2013 Jul; 51(7):1329-33. PubMed ID: 23729626
[No Abstract] [Full Text] [Related]
4. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
5. [1959-1999: from serum markers to 18-FDG in oncology. The experience of the René-Huguenin Center].
Pecking AP; Mechelany-Corone C; Pichon MF
Pathol Biol (Paris); 2000 Nov; 48(9):819-24. PubMed ID: 11141917
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules.
Bekci TT; Senol T; Maden E
J Int Med Res; 2009; 37(2):438-45. PubMed ID: 19383238
[TBL] [Abstract][Full Text] [Related]
7. The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3.
Bassi C; Salvia R; Gumbs AA; Butturini G; Falconi M; Pederzoli P
Langenbecks Arch Surg; 2002 Nov; 387(7-8):281-5. PubMed ID: 12447553
[TBL] [Abstract][Full Text] [Related]
8. Tumour markers in rheumatoid arthritis-associated interstitial lung disease.
Wang T; Zheng XJ; Ji YL; Liang ZA; Liang BM
Clin Exp Rheumatol; 2016; 34(4):587-91. PubMed ID: 27213221
[TBL] [Abstract][Full Text] [Related]
9. Indicators of inappropriate tumour marker use through the mining of electronic health records.
Gion M; Cardinali G; Trevisiol C; Zappa M; Rainato G; Fabricio ASC
J Eval Clin Pract; 2017 Aug; 23(4):895-902. PubMed ID: 28503788
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
Yang XQ; Chen C; Wang FB; Peng CW; Li Y
Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
[TBL] [Abstract][Full Text] [Related]
11. Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study.
Bjerner J; Høgetveit A; Wold Akselberg K; Vangsnes K; Paus E; Bjøro T; Børmer OP; Nustad K
Scand J Clin Lab Invest; 2008; 68(8):703-13. PubMed ID: 18609108
[TBL] [Abstract][Full Text] [Related]
12. [The determination of CA-125, CA-19-9 and CEA antigens in gynecologic patients for differential diagnosis and the assessment of the efficacy of surgical treatment and subsequent monitoring].
Alekseeva ML; Andreeva EN; Novikov EA; Fanchenko ND; Seliverstov AA; Bobkova MV; Margiani FR
Akush Ginekol (Mosk); 1995; (5):25-8. PubMed ID: 8579200
[TBL] [Abstract][Full Text] [Related]
13. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.
Wang HY; Hsieh CH; Wen CN; Wen YH; Chen CH; Lu JJ
PLoS One; 2016; 11(6):e0158285. PubMed ID: 27355357
[TBL] [Abstract][Full Text] [Related]
14. Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital.
Loi S; Haydon AM; Shapiro J; Schwarz MA; Schneider HG
Intern Med J; 2004; 34(9-10):545-50. PubMed ID: 15482267
[TBL] [Abstract][Full Text] [Related]
15. The impact of local guidelines on the tumour marker requesting patterns of a General Surgery Department.
Schulenburg-Brand D; Kumar N; Zouwail S
Ann Clin Biochem; 2013 Sep; 50(Pt 5):438-42. PubMed ID: 23828945
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of CEA, CA 125, and CA 15-3 serum tumour markers in different regions of Saudi Arabia.
Ashi A; Al-Hajeili M; Almaghrabi S; Al-Maghrabi J; Trabulsi N; Alghuraibi S; Alsiary R; Alrayes N
Saudi Med J; 2024 Jun; 45(6):565-571. PubMed ID: 38830664
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
18. [Impact of the implementation of a protocol for the adequate and safe use of tumor markers].
Mérida de la Torre FJ; Moreno Campoy EE; Martos Crespo F
Med Clin (Barc); 2015 Dec; 145(12):526-8. PubMed ID: 26169333
[TBL] [Abstract][Full Text] [Related]
19. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
Hui L; Rixv L; Xiuying Z
Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
[TBL] [Abstract][Full Text] [Related]
20. The value of serum tumour markers in the prediction of aetiology and follow up of patients with pericardial effusion.
Bildirici U; Celikyurt U; Acar E; Bulut O; Sahin T; Kozdag G; Ural D
Cardiovasc J Afr; 2012 Apr; 23(3):143-6. PubMed ID: 22555638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
